Globus Medical upgraded to neutral by BoA on Q4 performance
BofA Securities has upgraded Globus Medical (NYSE:GMED) to neutral from underperform, citing the company's strong Q4 revenue ...
manilatimes1h
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC”) reaches 1,003 of 1,224 ...